Suppr超能文献

三唑-棘白菌素联合用药对生物膜和浮游细胞中念珠菌属的活性。

Activities of triazole-echinocandin combinations against Candida species in biofilms and as planktonic cells.

机构信息

3rd Department of Pediatrics, Aristotle University, Hippokration Hospital, Konstantinoupoleos 49, GR-54642 Thessaloniki, Greece.

出版信息

Antimicrob Agents Chemother. 2011 May;55(5):1968-74. doi: 10.1128/AAC.00959-10. Epub 2011 Feb 22.

Abstract

Biofilm formation complicates the treatment of various infections caused by Candida species. We investigated the effects of simultaneous or sequential combinations of two triazoles, voriconazole (VRC) and posaconazole (PSC), with two echinocandins, anidulafungin (AND) and caspofungin (CAS), against Candida albicans and Candida parapsilosis biofilms in comparison to their planktonic counterparts. Antifungal activity was assessed by the 2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]2H-tetrazolium-5-carboxanilide (XTT) metabolic assay. Antifungal-agent interactions were analyzed by the Bliss independence model in the simultaneous-treatment studies and by analysis of variance (ANOVA) in the sequential-treatment studies. Against C. albicans planktonic cells, the simultaneous combination of PSC (32 to 128 mg/liter) and CAS (0.008 to 0.25 mg/liter) was synergistic; the combinations of PSC (128 to 1,024 mg/liter) with AND (0.03 to 0.5 mg/liter) and VRC (32 to 512 mg/liter) with AND (0.008 to 0.03 mg/liter) were antagonistic. Against C. parapsilosis planktonic cells, the interaction between VRC (32 to 1,024 mg/liter) and CAS (1 to 16 mg/liter) was antagonistic. All simultaneous antifungal combinations demonstrated indifferent interactions against biofilms of both Candida species. Damage to biofilms of both species increased (P<0.01) in the presence of subinhibitory concentrations of echinocandins (0.008 to 0.064 mg/liter), followed by the addition of PSC (512 mg/liter for C. albicans and 64 to 512 mg/liter for C. parapsilosis) or VRC (256 to 512 mg/liter for C. albicans and 512 mg/liter for C. parapsilosis). Triazole-echinocandin combinations do not appear to produce antagonistic effects against Candida sp. biofilms, while various significant interactions occur with their planktonic counterparts.

摘要

生物膜的形成使各种念珠菌引起的感染的治疗变得复杂。我们研究了两种三唑类药物伏立康唑(VRC)和泊沙康唑(PSC)与两种棘白菌素类药物阿尼芬净(AND)和卡泊芬净(CAS)同时或序贯联合应用对白色念珠菌和近平滑念珠菌生物膜的影响,并与浮游细胞进行了比较。抗真菌活性通过 2,3-双[2-甲氧基-4-硝基-5-磺苯基]-2H-四唑-5-羧基苯胺(XTT)代谢测定法进行评估。同时处理研究中采用 Bliss 独立性模型和序贯处理研究中采用方差分析(ANOVA)分析抗真菌药物相互作用。对浮游细胞的白色念珠菌,PSC(32 至 128 mg/L)与 CAS(0.008 至 0.25 mg/L)的同时组合具有协同作用;PSC(128 至 1024 mg/L)与 AND(0.03 至 0.5 mg/L)和 VRC(32 至 512 mg/L)与 AND(0.008 至 0.03 mg/L)的组合具有拮抗作用。对浮游细胞的近平滑念珠菌,VRC(32 至 1024 mg/L)与 CAS(1 至 16 mg/L)之间的相互作用具有拮抗作用。所有同时使用的抗真菌组合对两种念珠菌生物膜均表现出无差异的相互作用。在亚抑菌浓度的棘白菌素(0.008 至 0.064 mg/L)存在下,生物膜的损伤增加(P<0.01),随后加入 PSC(白色念珠菌为 512 mg/L,近平滑念珠菌为 64 至 512 mg/L)或 VRC(白色念珠菌为 256 至 512 mg/L,近平滑念珠菌为 512 mg/L)。三唑类-棘白菌素类药物联合应用似乎不会对念珠菌生物膜产生拮抗作用,而与浮游细胞相比,会产生各种显著的相互作用。

相似文献

1
Activities of triazole-echinocandin combinations against Candida species in biofilms and as planktonic cells.
Antimicrob Agents Chemother. 2011 May;55(5):1968-74. doi: 10.1128/AAC.00959-10. Epub 2011 Feb 22.
3
Additive antifungal activity of anidulafungin and human neutrophils against Candida parapsilosis biofilms.
J Antimicrob Chemother. 2011 Mar;66(3):588-91. doi: 10.1093/jac/dkq466. Epub 2010 Dec 7.
4
Differential activities of newer antifungal agents against Candida albicans and Candida parapsilosis biofilms.
Antimicrob Agents Chemother. 2008 Jan;52(1):357-60. doi: 10.1128/AAC.00856-07. Epub 2007 Oct 15.
6
Multilaboratory testing of two-drug combinations of antifungals against Candida albicans, Candida glabrata, and Candida parapsilosis.
Antimicrob Agents Chemother. 2011 Apr;55(4):1543-8. doi: 10.1128/AAC.01510-09. Epub 2011 Jan 31.
7
In vitro activity of antifungal combinations against Candida albicans biofilms.
J Antimicrob Chemother. 2010 Feb;65(2):271-4. doi: 10.1093/jac/dkp429. Epub 2009 Dec 8.
8
9
Interaction of the echinocandin caspofungin with amphotericin B or voriconazole against Aspergillus biofilms in vitro.
Antimicrob Agents Chemother. 2012 Dec;56(12):6414-6. doi: 10.1128/AAC.00687-12. Epub 2012 Oct 1.

引用本文的文献

1
Antibiofilm activity of manogepix, ibrexafungerp, amphotericin B, rezafungin, and caspofungin against spp. biofilms of reference and clinical strains.
Antimicrob Agents Chemother. 2025 Jun 4;69(6):e0013725. doi: 10.1128/aac.00137-25. Epub 2025 May 15.
4
Osteoarticular Mycoses.
Clin Microbiol Rev. 2022 Dec 21;35(4):e0008619. doi: 10.1128/cmr.00086-19. Epub 2022 Nov 30.
5
Activity of Amphotericin B Formulations and Voriconazole, Alone or in Combination, against Biofilms of and Fusarium spp.
Antimicrob Agents Chemother. 2021 Oct 18;65(11):e0063821. doi: 10.1128/AAC.00638-21. Epub 2021 Aug 9.
6
A Screen for Small Molecules to Target Biofilms.
J Fungi (Basel). 2020 Dec 27;7(1):9. doi: 10.3390/jof7010009.
7
Relationship between antifungal susceptibility profile and virulence factors in Candida albicans isolated from nail specimens.
Rev Soc Bras Med Trop. 2020 Feb 7;53:e20190214. doi: 10.1590/0037-8682-0214-2019. eCollection 2020.
8
Simvastatin inhibits planktonic cells and biofilms of Candida and Cryptococcus species.
Braz J Infect Dis. 2015 Sep-Oct;19(5):459-65. doi: 10.1016/j.bjid.2015.06.001. Epub 2015 Jun 26.
10
In vitro interactions between farnesol and fluconazole, amphotericin B or micafungin against Candida albicans biofilms.
J Antimicrob Chemother. 2015 Feb;70(2):470-8. doi: 10.1093/jac/dku374. Epub 2014 Oct 6.

本文引用的文献

1
Azole binding properties of Candida albicans sterol 14-alpha demethylase (CaCYP51).
Antimicrob Agents Chemother. 2010 Oct;54(10):4235-45. doi: 10.1128/AAC.00587-10. Epub 2010 Jul 12.
2
Genetic basis of Candida biofilm resistance due to drug-sequestering matrix glucan.
J Infect Dis. 2010 Jul 1;202(1):171-5. doi: 10.1086/651200.
4
In vitro activity of antifungal combinations against Candida albicans biofilms.
J Antimicrob Chemother. 2010 Feb;65(2):271-4. doi: 10.1093/jac/dkp429. Epub 2009 Dec 8.
7
Posaconazole for paediatric patients: status of development and future perspectives.
Mycoses. 2008 Sep;51 Suppl 2:5-11. doi: 10.1111/j.1439-0507.2008.01569.x.
8
Differential activities of newer antifungal agents against Candida albicans and Candida parapsilosis biofilms.
Antimicrob Agents Chemother. 2008 Jan;52(1):357-60. doi: 10.1128/AAC.00856-07. Epub 2007 Oct 15.
9
Clinical pharmacology of antifungal agents in pediatric patients.
Expert Opin Pharmacother. 2007 Oct;8(15):2465-89. doi: 10.1517/14656566.8.15.2465.
10
Intravascular catheter-related infections: advances in diagnosis, prevention, and management.
Lancet Infect Dis. 2007 Oct;7(10):645-57. doi: 10.1016/S1473-3099(07)70235-9.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验